Yildiz BO, Boguszewski CL, da Silva Boguszewski MC, Busetto L, Celik O et al (2024) EndoBridge 2023: highlights and pearls hormones. (Athens) 23:183–204. https://doi.org/10.1007/s42000-024-00549-8

Article  Google Scholar 

Kamilaris CDC, Stratakis CA (2019) Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol (Lausanne) 10:339. https://doi.org/10.3389/fendo.2019.00339

Article  PubMed  Google Scholar 

Alrezk R, Hannah-Shmouni F, Stratakis CA (2017) MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer 24(10):T195–T208. https://doi.org/10.1530/ERC-17-0243

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stratakis CA, Kirschner LS, Carney JA (2001) Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 86(9):4041–4046. https://doi.org/10.1210/jcem.86.9.7903

Article  CAS  PubMed  Google Scholar 

Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO et al (2014) Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation. N Engl J Med 18;371(25):2363-74. https://doi.org/10.1056/NEJMoa1408028

Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA et al (2015) Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab 100(5):E710–E719. https://doi.org/10.1210/jc.2014-4297

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larkin S, Ansorge O, Pathology And Pathogenesis of Pituitary Adenomas And Other Sellar Lesions (2017). Feb 15. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 28402620

Giustina A, Biermasz N, Casanueva FF et al (2024) Acromegaly consensus group. consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7–22. https://doi.org/10.1007/s11102-023-01360-1

Article  CAS  PubMed  Google Scholar 

Orme S, McNally R, James PW et al (2016) UK acromegaly register study group. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK acromegaly register 1970–2016. Clin Endocrinol (Oxf) 100(6):558–564. https://doi.org/10.1111/cen.15060

Article  Google Scholar 

Raverot G, Burman P, McCormack A et al (2018) European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1–G24. https://doi.org/10.1530/EJE-17-0796

Article  CAS  PubMed  Google Scholar 

McCormack A, Dekkers OM, Petersenn S et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European society of endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265–276. https://doi.org/10.1530/EJE-17-0933

Article  CAS  PubMed  Google Scholar 

Burman P, Trouillas J, Losa M et al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187(4):593–605. https://doi.org/10.1530/EJE-22-0440

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM (2023) Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. J Clin Endocrinol Metab 108(7):1585–1601. https://doi.org/10.1210/clinem/dgad098

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C (2020) How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 12(2). https://doi.org/10.3390/cancers12020514

Lin AL, Rudneva VA, Richards AL et al (2024) Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors. Acta Neuropathol 147(1):85. https://doi.org/10.1007/s00401-024-02736-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin AL, Jonsson P, Tabar V et al (2018) Marked response of a hypermutated ACTH-Secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab 103(10):3925–3930. https://doi.org/10.1210/jc.2018-01347

Article  PubMed  PubMed Central  Google Scholar 

Cooper DS, Biondi B (2012) Subclinical thyroid disease. Lancet 24;379(9821):1142-54. https://doi.org/10.1016/S0140-6736(11)60276-6

Biondi B, Cappola AR, Cooper DS (2019) Subclinical hypothyroidism. JAMA 322(2):153–160

CAS  PubMed  Google Scholar 

Biondi B, Cooper DS (2018) Subclinical Hyperthyroidism. N Engl J Med 11;379(15):1485–1486. https://doi.org/10.1056/NEJMc1809627

Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ (2015) The 2015 European thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J 4(3):149–163. https://doi.org/10.1159/000438750

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biondi B (2024) Atrial fibrillation and stroke: updated evidence on a screening program according to serum TSH. J Clin Endocrinol Metab:dgae777. https://doi.org/10.1210/clinem/dgae777

Article  Google Scholar 

Högler W, Briody J, Woodhead HJ, Chan A, Cowell CT (2003) Importance of lean mass in the interpretation of total body densitometry in children and adolescents. J Pediatr 143(1):81–88. https://doi.org/10.1016/S0022-3476(03)00187-2

Article  PubMed  Google Scholar 

Crabtree NJ, Kibirige MS, Fordham JN, Banks LM, Muntoni F, Chinn D, Boivin CM, Shaw NJ (2004) The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 35(4):965–972. https://doi.org/10.1016/j.bone.2004.06.009

Article  CAS  PubMed  Google Scholar 

Płudowski P, Lebiedowski M, Olszaniecka M, Marowska J, Matusik H, Lorenc RS (2006) Idiopathic juvenile osteoporosis–an analysis of the muscle-bone relationship. Osteoporosis international, 2006. 17(11):1681-90. https://doi.org/10.1007/s00198-006-0183-1

Schoenau E, Neu CM, Beck B, Manz F, Rauch F (2002) Bone mineral content per muscle cross-sectional area as an index of the functional muscle‐bone unit. J Bone Miner Res 17(6):1095–1101. https://doi.org/10.1359/jbmr.2002.17.6.1095

Article  PubMed  Google Scholar 

Guss CE, McAllister A, Gordon CM (2021) DXA in children and adolescents. J Clin Densitometry 24(1):28–35. https://doi.org/10.1016/j.jocd.2020.01.006

Article  Google Scholar 

Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11(5):401–419. https://doi.org/10.1038/nrd3705

Article  CAS  PubMed  Google Scholar 

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513–523. https://doi.org/10.1016/S2213-8587(17)30138-9

Article  CAS  PubMed  Google Scholar 

Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW (2015) Sustained Modeling-Based bone formation during adulthood in cynomolgus monkeys May contribute to continuous BMD gains with denosumab. J Bone Min Res 30(7):1280–1289. https://doi.org/10.1002/jbmr.2480

Article  CAS  Google Scholar 

Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19(5):307–317. https://doi.org/10.1038/s41584-023-00935-3

Article  CAS  PubMed  Google Scholar 

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 20(8):756–765. https://doi.org/10.1056/NEJMoa0809493

Article  CAS  Google Scholar 

Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97(9):3161–3169. https://doi.org/10.1210/jc.2012-1569

Article  CAS  PubMed  Google Scholar 

Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double- dummy, non-inferiority study. Lancet Diabetes Endocrinol 6(6):445–454. https://doi.org/10.1016/S2213-8587(18)30075-5

Article  CAS  PubMed